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This Perspective will discuss the physiologic relevance of data that suggest CNS insulin action is required for
the rapid suppression of hepatic glucose production. It will also review data from experiments on the
conscious dog, which show that although the canine brain can sense insulin and, thereby, regulate hepatic
glucoregulatory enzyme expression, CNS insulin action is not essential for the rapid suppression of glucose
production caused by the hormone. Insulin’s direct hepatic effects are dominant, thus it appears that insulin’s
central effects are redundant in the acute regulation of hepatic glucose metabolism.Introduction
Insulin is a primary regulator of hepatic glucose metabolism in
healthy individuals. Failure of the liver to appropriately respond
to insulin (hepatic insulin resistance) is an underlying cause of
the increased hepatic glucose production (HGP) and hypergly-
cemia associated with type 2 diabetes. Therefore, elucidating
mechanisms that are fundamental to the insulin-mediated
control of HGP and understanding the loss of this control in the
insulin resistant state remain priorities in the field. Insulin is
known to rapidly suppress HGP through its direct action at the
liver and also through indirect effects thought to be mediated
primarily at adipose tissue and the a-cell (Figure 1) (Bergman,
1997; Cherrington, 1999; Rizza, 2010). In the past decade,
studies in rodents have suggested that insulin signaling in the
central nervous system (CNS) also has the ability to modify
neural input to the liver and, as a result, suppress HGP (Guo
et al., 2009; Hill et al., 2010; Inoue et al., 2006; Koch et al.,
2008; Ko¨nner et al., 2007; Lin et al., 2010; Obici et al., 2002a,
2002b; Ono et al., 2008; Park et al., 2009; Pocai et al., 2005).
In addition, CNS insulin action has been suggested to suppress
adipose tissue lipolysis (Scherer et al., 2011) and a-cell glucagon
secretion (Paranjape et al., 2010), thereby providing additional
potential mechanisms for central control of HGP (Figure 1).
Furthermore, some studies of CNS insulin action have sug-
gested that the central effect of insulin is required for the rapid
suppression of HGP in response to increased insulin secretion
(Obici et al., 2002b; Pocai et al., 2005). Moreover, it has been
suggested that targeting CNS insulin resistance may be of value
in the treatment of human type 2 diabetes (Sandoval et al., 2009).
Whether insulin’s central arm is conserved in, or relevant to,
the regulation of hepatic glucose production in humans is
unknown. To help address this uncertainty, we have been
studying CNS insulin action and its effects on HGP in the con-
scious dog, a model in which glucose metabolism is similar to
the human in several regards (e.g., the basal rate of HGP and
slow depletion of liver glycogen). Our studies suggest that the
insulin-CNS-liver signaling axis characterized in the rodent is
conserved in the dog, but that the rapid and marked inhibitory656 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.effect of insulin on HGP does not depend on this mechanism
for its effect. This Perspective will first discuss the data, which
have been interpreted to support the notion that insulin’s central
action is necessary for the rapid regulation of HGP. We will then
focus on limitations of the methods that have been used to study
brain insulin action on the liver in vivo. Finally, we will review the
evidence from experiments in humans and dogs indicating that
acute changes in CNS insulin action are not essential for the
hormone’s rapid inhibitory control of hepatic glucose produc-
tion; instead this mechanism appears to be masked in the pres-
ence of insulin’s prominent non-CNS effects.
The Case for CNS Insulin Action in the Acute Regulation
of HGP
Although classic studies established that CNS insulin can
regulate energy homeostasis (Woods et al., 1979) and pancre-
atic hormone secretion (Woods and Porte, 1975), until recently
there had been little evidence indicating that CNS insulin could
directly regulate HGP. Interest in insulin’s central action was
significantly enhanced by a provocative study in which rats
were infused with either vehicle or insulin through an intracere-
broventricular (ICV) cannula (Obici et al., 2002b). By the fourth
hour of treatment, ICV insulin had not caused any alteration in
glucose metabolism or pancreatic hormone secretion when
compared to vehicle-infused controls. Both groups were then
subjected to a pancreatic clamp, in which somatostatin was
used to inhibit endogenous insulin and glucagon secretion,
and insulin, but not glucagon, was replaced via a peripheral
vessel at a rate (1.0 mU/kg/min) calculated to maintain arterial
plasma insulin levels at basal values. During the last hour of
the 2 hr clamp (the sixth hour of infusion), ICV insulin was asso-
ciated with a 30% decrease in HGP relative to the rate in an ICV
vehicle-infused control group (which decreased from basal
by 10%). In addition, in a separate experiment of the same
duration, interruption of central insulin action (by ICV infusion
of hypothalamic insulin signaling or KATP channel inhibitors for
six hours) substantially reduced suppression of HGP caused
by hyperinsulinemia resulting from peripheral vein infusion of
Figure 1. The Control of Hepatic Glucose
Production by Insulin
Insulin suppresses HGP by both direct (hepatic insulin
receptor signaling) and indirect effects. The indirect
effects of insulin on the liver include inhibition of lipolysis in
adipocytes, reduction in glucagon secretion by the a-cells
of the pancreas, and (in rodents) a decrease in vagal
efferent signaling to the liver per se. In addition, insulin
action in the brain may also inhibit glucagon secretion and
decrease lipolysis, thus reinforcing insulin’s direct actions
on these tissues. Not shown are the effects of insulin on
gluconeogenic substrate supply from muscle, which are
typically minor unless insulin is increased dramatically
(Edgerton et al., 2009a). The relative contribution of each
pathway to the control of liver glucose metabolism may
vary depending on experimental conditions, metabolic
state, and differences in species.
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2002b). These data led the authors to conclude that activation of
the insulin-brain-liver signaling axis is required for the rapid
action of insulin on glucose production.
Genetic manipulation of the insulin receptor (IR) or insulin-
mediated events in the entire CNS (Bru¨ning et al., 2000; Koch
et al., 2008; Lin et al., 2011), the hypothalamus (Obici et al.,
2002a; Ono et al., 2008), or specific populations of hypotha-
lamic neurons (Hill et al., 2009, 2010; Ko¨nner et al., 2007; Lin
et al., 2010) have supported the notion that CNS insulin action
plays a role in the suppression of HGP. This suppression requires
intact vagus efferent nerves in both rats and mice (Pocai et al.,
2005) but may be independent of hepatic muscarinic acetylcho-
line (the major neurotransmitter released from vagal efferent
nerve endings) receptor signaling (Li et al., 2009). In any case,
it has been suggested that the brain insulin-mediated reduction
in HGP requires hepatic IL6 expression (Inoue et al., 2006; Ko¨n-
ner et al., 2007), hepatic STAT3 phosphorylation (Inoue et al.,
2006; Koch et al., 2008) and appears to be achieved via suppres-
sion of gluconeogenesis (Pocai et al., 2005). The latter was
associated with reductions in the expression of gluconeogenic
mRNA (PEPCK, G6Pase) (Inoue et al., 2006; Pocai et al., 2005)
and protein (G6Pase) (Ko¨nner et al., 2007). In addition, rodent
studies have indicated that long-term decreases in CNS insulin
action can impair the response of HGP to insulin in models of
insulin resistance (Hill et al., 2009, 2010; Koch et al., 2008; Ko¨n-
ner et al., 2007; Lin et al., 2010; Ono et al., 2008; Park et al.,
2009). Furthermore, chronic increases in CNS insulin action by
either genetic overexpression of hypothalamic insulin signaling
proteins (Gelling et al., 2006) or prolonged ICV insulin infusion
(Park et al., 2009) improved the acute response to insulin-regu-
lated glucose metabolism in diabetic animals.
Methodological Limits to In Vivo CNS Insulin Studies
Insulin and glucagon distribution during the peripheral insulin
clamp. The peripheral basal insulin clamp frequently used in
rodents and humans involves the infusion of somatostatin and
insulin into a peripheral blood vessel. Unfortunately, this ablatesCell Methe normal physiologic gradient of insulin and
glucagon that exists between hepatic and non-
hepatic tissues. Under normal circumstances,
insulin and glucagon are both secreted into the
portal vein and are subject to considerableextraction by the liver. For insulin, this creates a gradient
across the liver such that hepatic insulin levels are 3-fold that
of the insulin levels at nonhepatic tissues, including the brain
(Horwitz et al., 1975; Moore et al., 2002). During a basal insulin
clamp protocol (peripheral vein insulin infusion at a rate of
1.0 mU/kg/min), arterial insulin levels are maintained at basal
values, but because endogenous insulin secretion is eliminated,
marked hepatic insulin deficiency occurs simultaneously (Fig-
ure 2). The hyperglycemia expected to result from hepatic insulin
deficiency can be avoided if glucagon, the primary driver for
basal HGP in rodents, dogs, and humans (Brand et al., 1995;
Cherrington et al., 1978; Liljenquist et al., 1977) is not replaced.
Thus, in studies in which this approach was used, the central
effects of ICV insulin were observed at a time when the liver
was deficient in two of its primary regulatory signals, insulin
and glucagon.
CNS insulin action has also been studied using the hyperinsu-
linemic clamp, with or without somatostatin infusion. In this
setting, insulin is infused into a peripheral blood vessel at a rate
(typically 3.0–3.6 mU/kg/min) designed to cause arterial hyperin-
sulinemia. The physiologic insulin gradient is again disrupted
because the fold increase in insulin at the liver will be markedly
less than that at the brain, a situation that does not occur when
insulin secretion increases. This relative hepatic insulin deficiency
is likely to lead to an overestimation of the importance of insulin’s
nonhepatic (including CNS) mechanisms in regulating HGP rela-
tive to what occurs in normal physiology. In addition, hyperinsuli-
nemia resulting from insulin infusion has been shown to decrease
glucagon secretion (Cherrington, 2001), perhaps due, in part, to
CNS insulin-mediated effects on the a-cell (Paranjape et al.,
2010). Thus, a fall in hepatic glucagon levels would also be ex-
pected to occur during a hyperinsulinemic clamp, regardless of
whether or not somatostatin is infused, and this may contribute,
directly or indirectly, to the suppression of HGP. Given these
considerations, it is difficult to judge, based on existing clamp
data in the rodent, the relevance of CNS insulin signaling to the
control of HGP under normal physiologic conditions (i.e., when
relative levels of insulin and glucagon at the liver are normal).tabolism 15, May 2, 2012 ª2012 Elsevier Inc. 657
Figure 2. Hepatic and Nonhepatic Insulin Levels during the Basal
State and during the Basal Peripheral Vein Insulin Clamp
Arterial data are redrawn from Obici et al. (Obici et al., 2002b), and hepatic
portal vein and hepatic sinusoidal levels were estimated based on the arterial-
portal insulin gradients resulting from endogenous secretion or peripheral vein
infusion (Chu et al., 2004;Moore et al., 2002). Because of high first-pass insulin
clearance, hepatic insulin levels are3-fold greater than concentrations in the
artery. During the clamp, somatostatin is infused and nonhepatic (arterial)
insulin levels are maintained at basal, while liver insulin levels are markedly
deficient. Stimulation of hepatic glucose production can be avoided if
glucagon is not replaced.
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sions are experimental tools that have been used extensively
to study the effects of a selective rise in insulin in the CNS on
peripheral (i.e., non-CNS) glucose metabolism. Insulin infused
directly into the brain can reach hypothalamic centers relevant
to whole-body glucose metabolism, yet this manner of delivery
is nonphysiologic in terms of route and, probably, dose. It is
unknown how insulin perfusion of CNS tissue during ICV/IH
administration compares to the perfusion present when the
hormone enters physiologically through the vasculature. ICV/IH
infusions may well cause nonphysiologic regionalization of the
administered insulin. This is an important consideration because
although hypothalamic tissue is easily accessed during ICV/IH
infusion, access to distal centers in the brain that can regulate
glucose metabolism may be limited (Levin and Sherwin, 2011).
This limitation can be avoided through the infusion of insulin
into the carotid and vertebral arteries, allowing brain insulin
levels to be selectively elevated using the physiological route.
Blockade of brain insulin signaling. There are several consider-
ations inherent in ICV administration of PI3K inhibitors (e.g.,
LY294002) to disrupt CNS insulin action. First, insulin can acti-
vate signaling via pathways other than PI3K. This may not be a
significant issue, however, because Obici et al. found that PI3K
but not MAP kinase was involved in the insulin-brain-liver sig-
naling axis (Obici et al., 2002b). Second, the neurons targeted
by insulin reaching the brain from the circulation may differ
from those targeted by a PI3K inhibitor given ICV, because ICV
delivery results in concentrations at ventricular surfaces that
are likely to be greater than those occurring at deeper sites. In
previous studies, however, administration of inhibitors gener-
ated similar effects regardless of site of infusion (ICV or IH),
suggesting that the neurons in the hypothalamus that are
responsible for the effects of brain insulin at the liver are acces-
sible to small-molecule inhibitors via the ICV route, and that
possible blockade of PI3K at nonhypothalamic sites did not658 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.contribute to the observed brain insulin response (Pocai et al.,
2005). Third, PI3K is not only involved in insulin signaling (e.g.,
leptin also signals through this pathway) (Hawkins et al., 2006;
Warne et al., 2011), but this is probably not a problem when
one is examining the effects of a selective rise in insulin if a base-
line LY294002 control experiment is included. Finally, LY294002
could have off-target (non-PI3K) effects (Gharbi et al., 2007).
Studies performed by the Rossetti group (Obici et al., 2002b;
Pocai et al., 2005), however, showed that the effects of brain
insulin signaling on HGP could be blocked as effectively by
ICV infusion of PI3K inhibitors as by ICV or IH injection of insulin
antibodies, insulin receptor antisense oligonucleotides, or KATP
channel inhibitors. This suggests that ICV administration of
PI3K inhibitors to acutely block brain insulin action is a reason-
able approach.
Evidence Against a Role for CNS Insulin Action
in the Acute Control of HGP in Large Animals
In light of the array of rodent data referred to previously, there is
a need to critically evaluate the role of CNS insulin action in the
regulation of HGP in humans. Obviously, such experiments are
extremely difficult to carry out. Therefore, in order to address
this question in a large animal model, we have been examining
central insulin action in the dog. This model allows for the infu-
sion of insulin into the hepatic portal vein and the carotid and
vertebral arteries and for the calculation of net hepatic glucose
balance (i.e., the net of hepatic glucose production and uptake)
to complement tracer-derived estimation of HGP. To date, we
have evaluated the importance of CNS insulin action in a variety
of ways using the portal vein pancreatic clamp technique under
euglycemic conditions. Since glucagon was clamped at a basal
value, this would cause us to underestimate the importance of
CNS insulin action on HGP to the extent that a rise in hypotha-
lamic insulin suppresses glucagon secretion (Paranjape et al.,
2010). Nevertheless, use of the portal vein pancreatic clamp in
combination with a glucose clamp allows us to carefully assess
the regulatory importance of the insulin-brain-liver signaling axis
(Figure 1), independent of changes in circulating glucagon or
glucose levels.
In studies performed a number of years ago, we first examined
the mechanism by which a selective rise in insulin at nonhepatic
tissues (i.e., brain, muscle, and fat) can suppress HGP in the
presence of basal insulin at the liver (Sindelar et al., 1997).
Initially, in the control period, insulin and glucagon were infused
at basal rates into the portal vein of dogs. During the experi-
mental period, the portal vein insulin infusion rate was
decreased, and at the same time insulin was infused into a
peripheral vein to bring about a selective 3-fold increase in
insulin at nonhepatic tissues while maintaining basal insulin
levels at the liver. Selective nonhepatic hyperinsulinemia sup-
pressed net hepatic glucose output and HGP with a time course
corresponding to the time course of the decrease in circulating
NEFA levels. When this fall in NEFA was prevented using intrali-
pid infusion, the suppression of net hepatic glucose output and
HGP was blocked. These data and those of others (Rebrin
et al., 1996) suggest that the insulin-driven suppression of lipol-
ysis (and not CNS insulin-driven input to the liver) was respon-
sible for the acute inhibition of hepatic glucose production in
response to modest nonhepatic hyperinsulinemia.
Figure 3. Model for the Insulin-Brain-Liver Signaling Axis in the Dog
Increased hypothalamic insulin signaling causes an increase in hepatic signal
transducer and activator of transcription 3 (STAT3) phosphorylation. Phos-
phorylated STAT3 reduces the gluconeogenic gene and protein expression of
phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase
(G6Pase), and pyruvate carboxylase (PC). Glycogen synthase kinase-3 beta
(GSK3b) gene and protein expression are also reduced by STAT3, leading to
the activation of glycogen synthase (GS). In addition, brain insulin induces
glucokinase (GK) gene expression; this effect is associated with a decrease in
SHP protein, a negative regulator of GK expression. During a basal pancreatic
clamp (hepatic sinusoidal insulin and glucagon and arterial NEFA and glucose,
all clamped at basal values), brain insulin action does not acutely alter
gluconeogenesis or hepatic glucose production in the dog, despite sup-
pressing gluconeogenic gene expression. Central insulin action does,
however, stimulate hepatic glucose uptake and glycogen synthesis associ-
ated with the genetic regulation of GSK3b. During physiologic hyper-
insulinemia, brain insulin action does not impact the rapid suppression of
hepatic glucose metabolism.
Cell Metabolism
PerspectiveIn another study, we assessed the relative importance of the
direct (hepatic) and indirect (nonhepatic; i.e., muscle, adipose,
and CNS) effects of insulin on HGP (Edgerton et al., 2006).
Dogs were first maintained on a basal pancreatic clamp using
portal vein infusion of insulin and glucagon. During the experi-
mental period, the insulin infusion was switched from the portal
vein to a leg vein, thereby bringing about an 2-fold increase
in arterial insulin (i.e., at nonhepatic tissues) and an 50%
decline in insulin at the liver. Net hepatic glucose output and
HGP were markedly increased as a result of hepatic insulin defi-
ciency, rather than suppressed as a result of increased nonhe-
patic (including the CNS) hyperinsulinemia. In another group of
animals, the basal insulin infusion was switched from the portal
vein to the carotid and vertebral arteries, rather than a leg vein,
thereby increasing CNS insulin 4-fold. Once again, there was
a 50% fall in insulin at the liver, and net hepatic glucose output
and HGP increased as they did when the insulin infusion was
switched to a leg vein. Thus, additional CNS insulin enrichment
had no effect on the metabolic response to hepatic insulin defi-
ciency. These data clearly indicate the importance of the direct
effect of insulin on the liver to the basal rate of glucose produc-
tion.
Given the design of the above studies, it is possible that we did
not detect CNS insulin-mediated regulation of hepatic glucose
metabolism because the brain hyperinsulinemia that we em-ployed was too low. Thus, we set about to examine the effects
of greater brain hyperinsulinemia on the liver. Our first aim was
to determine if the insulin-brain-liver signaling axis characterized
in rodents exists in the dog. To do so, we infused insulin via an
ICV cannula at the same dose observed to suppress HGP in
the rat (Obici et al., 2002b) during a basal intraportal insulin
and glucagon clamp. ICV insulin was able to increase hypotha-
lamic pAkt 3.5-fold and hepatic pSTAT3 2.9-fold and suppress
the mRNA expression of pyruvate carboxylase, G6Pase, and
PEPCK by 30%–60% (Ramnanan et al., 2011a). Even though
CSF insulin levels increased 200 fold, far above what would
ever happen in the intact animal, and despite the fact that gluco-
neogenic mRNA expression was suppressed (as in rodents), ICV
insulin treatment did not significantly alter either net or absolute
basal glucose production over the 4h observation period. Of
importance, however, these studies proved that the canine brain
can sense acute increases in plasma insulin and, as a result,
modify glucoregulatory gene expression in the liver.
As noted earlier, there are inherent difficulties in interpreting
the physiologic relevance of ICV insulin infusion. Therefore,
our next goal was to evaluate whether a substantial, but more
physiologic (in terms of vascular route and dose), increase in
CNS insulin could modify hepatic glucose flux in the dog. There-
fore, we infused insulin bilaterally into the carotid and vertebral
arteries to increase the CNS insulin level 10-fold, while at the
same time using clamp techniques to fix hepatic sinusoidal
insulin and glucagon, and arterial glucose and NEFA levels, at
basal values (Ramnanan et al., 2011a). The experiment was
carried out both in the presence (ICV aCSF infusion) and
absence (ICV infusion of a PI3K inhibitor) of hypothalamic insulin
signaling. Brain hyperinsulinemia did not alter hepatic glucose
production, gluconeogenesis, or glycogenolysis but was able
(in the fourth hour) to reduce net hepatic glucose balance as a
result of altered net hepatic glycogen metabolism. That CNS
insulin reduced net hepatic glucose balance without altering
HGP implied that the effect was due to the stimulation of
hepatic glucose uptake and glycogen synthesis. The slow
time course of the effect suggested regulation at the genetic
level (Figure 3). In accord with that finding, we observed that
brain hyperinsulinemia increased glucokinase mRNA and
decreased the mRNA and protein levels of GSK3b, another
STAT3-regulated gene (Moh et al., 2008). Reduced GSK3b
protein was associated with decreased glycogen synthase
phosphorylation, which resulted in enhanced glycogen syn-
thase activity (Figure 3). ICV administration of a PI3K inhibitor
(LY294002) had no effect in the presence of basal insulin levels
but inhibited hypothalamic Akt phosphorylation and blocked the
centrally mediated downstream molecular consequences of
increased insulin in the liver, as well as the associated changes
in glucose kinetics.
The dog and rodent studies described above all defined
brain insulin’s effects in the context of relative hepatic insulin
deficiency (Figure 2). It should be kept in mind that when the
pancreas secretes insulin into the portal vein, the absolute
magnitude of the rise in plasma insulin at the liver will be approx-
imately three times greater than at the brain. It is, therefore,
possible that when appropriate hyperinsulinemia occurs at the
liver, the effects of brain hyperinsulinemia will be masked,
meaning that CNS insulin action would have no impact on theCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 659
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Alternatively, there may be interaction between the effects of
acute changes in brain and liver hyperinsulinemia, such that
both are required to bring about a full hepatic response.
In light of these uncertainties, we determined the role of brain
insulin action in the regulation of HGP in the context of a simu-
lated increase in insulin secretion, such that the level of the
hormone in plasma increased simultaneously by the same fold
at all tissues of the body, including brain, muscle, fat, and liver
(Cherrington, A.D., unpublished data; Edgerton et al., 2009b;
Ramnanan et al., 2011b). When both brain hyperinsulinemia
and hepatic hyperinsulinemia were present, direct hepatic insulin
signaling controlled the hepatic gluconeogenic program, brain
insulin signaling controlled hepatic GSK3b expression, and the
induction of glucokinase expression was under dual brain- and
hepatic insulin-mediated regulation. Nongenomic effects of
brain insulin action on hepatic glucose production were not
apparent, however, and CNS insulin action had no bearing on
the acute suppression of lipolysis during physiologic hyperinsu-
linemia. Because of the lack of effects of brain insulin action on
the liver, adipose tissue, or muscle, the rapid regulation of
hepatic glucose metabolism by physiologic increases in insulin
occurred independent of the acute increase in CNS insulin
action, despite differential genetic regulation. Our data thus indi-
cate that the acute effects of CNS insulin action on whole-body
glucose kinetics are overwhelmed by the consequences of the
hormone’s noncentral actions.
Evidence for CNS Control of HGP in the Human
Although the question of brain insulin action is difficult to address
in the human, a recent study showed that oral administration of a
KATP channel activator decreased HGP modestly (30%) in
nondiabetic humans; however, inhibition was first apparent
more than 5 hr after oral diazoxide consumption and was
observed during a peripheral vein insulin clamp (Kishore et al.,
2011). In rodent studies, hypothalamic KATP channel activation
replicated the effect of ICV insulin administration on HGP, and
coadministration of a KATP channel inhibitor blocked brain insulin
action (Obici et al., 2002b; Pocai et al., 2005). Because activation
of the KATP channel suppressed HGP in the human (Kishore
et al., 2011), it raises the possibility that brain insulin action has
the potential to regulate liver glucose metabolism in man, as it
can in the rodent and the dog. It must be remembered, however,
that the effect was slow tomanifest and its physiologic relevance
is unclear because, once again, the inhibition of HGP was
observed during relative hepatic insulin deficiency. Further,
whereas HGP responds to insulin within minutes in the human
and because 5h after diazoxide consumption there was no
effect on HGP, these data do not support the notion that acute
changes in brain insulin action play a role in the rapid regulation
of HGP.
Hepatic Denervation Does Not Adversely Affect Insulin-
Mediated Control of HGP
Liver-transplanted (Lx) humans show no evidence of hepatic
reinnervation for at least 30 months post-surgery (Kjaer et al.,
1994). Thus, such patients can serve as a loss-of-function
model, where hepatic glucose metabolism can be studied in
the absence of any CNS input (including insulin-mediated input)660 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.to the liver. Interpretation of data is complicated by immunosup-
pressive therapy in such patients, but this can be controlled for,
at least in part, by comparison to carefully matched kidney-
transplanted (Kx) patients or individuals with chronic uveitis
(CU) who were maintained on similar treatment regimens.
Fasting plasma glucose and insulin levels of Lx patients were
comparable to those of CU or Kx patients throughout the post-
surgery follow-up period (up to 28 months) (Luzi et al., 1997;
Perseghin et al., 1997; Schneiter et al., 2000a; Schneiter et al.,
2000b). The suppression of HGP in Lx patients during hyperinsu-
linemic-hyperglycemic, euinsulinemic-hyperglycemic, and hy-
perinsulinemic-euglycemic clamps was similar to that observed
in CU patients and healthy controls (Luzi et al., 1997; Perseghin
et al., 1997). Following an oral glucose load, net hepatic
glycogen synthesis (a correlate to hepatic glucose uptake) and
the reduction in the rate of glucose appearance was similar in
Lx and Kx patients compared to healthy controls studied
2–6 weeks after surgery (Schneiter et al., 2000b). The same Lx
patients featured exaggerated postprandial glucose levels, rela-
tive to Kx patients, following an oral glucose load 38 weeks after
surgery (Schneiter et al., 2000a), although this impaired glucose
tolerance was likely due to relative circulating hypoinsulinemia
(secondary to increased hepatic insulin clearance) rather than
impaired hepatic insulin sensitivity. Thus, it appears that the
regulation of HGP during fasting, insulin clamp, and postprandial
conditions is essentially normal in the Lx patient. Consistent with
this view, the incidence of new-onset diabetes following liver
transplantation is similar to what occurs with other transplanted
organs (Marchetti, 2004), suggesting that the total loss of neural
input to the liver does not predispose the human to the disease.
In support of these human data, the regulation of hepatic glucose
metabolism during the basal state and also during hyperinsuline-
mic clamps and feeding conditions (i.e., mixed meal, oral
glucose, or intraduodenal glucose challenges) was largely intact
in dogs (Moore et al., 1993, 1994, 2002) and rats (Kissler et al.,
2005) subjected to complete hepatic denervation.
It must be acknowledged, however, that neural input to the
liver is complex. Hepatic innervation involves input from para-
sympathetic (cholinergic) and sympathetic (adrenergic) nerves,
each carrying efferent and afferent fibers, as well as nonadrener-
gic/noncholinergic nerves (Yi et al., 2010). It is possible, for
instance, that the lack of insulin-mediated vagal input to the liver
(Pocai et al., 2005) is balanced and off-set by the lack of
opposing sympathetic drive in Lx patients, resulting in normal
insulin-mediated regulation of HGP. In support of this possibility
is the finding that the daily oscillations in plasma glucose and
hepatic glucoregulatory gene expression were normal in rats
subjected to complete hepatic denervation, but aberrant in
response to unilateral removal of either parasympathetic or
sympathetic input to the liver (Cailotto et al., 2008). It is also
possible that, in the absence of CNS insulin-mediated input to
the liver, peripheral insulin-mediated mechanisms compensate
in order to maintain normal hepatic glucose metabolism.
Further Considerations
Species differences. It should be noted that glucose metabolism
is different in rodents and large animals in several regards. To
begin with, basal rates of HGP after a short-term fast are 5- to
10-fold (per unit of body weight) greater in rodents than humans
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and, thus, the capacity for glycogenolysis, very quickly (within
a few hours), whereas humans and dogs maintain hepatic
glycogen, and significant glycogenolysis, even after 42 hr of fast-
ing (Hendrick et al., 1990; Nuttall et al., 2008). The gluconeogenic
pathway is, therefore, more critical for maintaining fasting HGP in
the rodent than in large animals. This may be important because
insulin action in the CNS is thought to suppress HGP in the
rodent by inhibiting gluconeogenesis (Pocai et al., 2005). There
are also species-dependent differences in hepatic innervation
(Yi et al., 2010), and it may be that increased the gluconeogenic
drive evident in rodents results in part from increased neural
input.
Time course of CNS insulin action. Physiologic hyperinsuline-
mia rapidly (within minutes) suppresses HGPwith marked inhibi-
tion evident within 1 hr (Ramnanan et al., 2010b). In addition, the
meal-associated b-cell response typically peaks within 1 hr, with
insulin secretion returning to basal within 3–4 hr as euglycemia is
restored. Moreover, the gluconeogenic pathway is not sup-
pressed by meal-associated hyperinsulinemia (Jin et al., 2003;
Newgard et al., 1984; Nuttall et al., 2008), despite insulin’s ability
to substantially suppress PEPCK protein expression (Ramnanan
et al., 2010b). Thus, it is unlikely that acute changes in brain
insulin signaling, which appears to involve the genetic regulation
of gluconeogenesis, would produce an effect on HGP during the
time course of a meal. Instead, it would appear that the nonge-
nomic (i.e., posttranslational) mechanisms are responsible for
the rapid insulin-mediated suppression of HGP (Lin and Accili,
2011; Ramnanan et al., 2010a).
Although our canine studies do not support a role for acute
changes in CNS insulin action in the rapid control of HGP, it is
possible that long-term alteration of CNS insulin signaling may
bring about important and sustained changes in hepatic glucor-
egulatory gene and protein expression, such that the response
to increased insulin secretion, via direct or indirect mechanisms,
would be altered. We examined the effects of brain insulin action
on the rapid (0–4 hr) suppression of HGP in the dog when brain
insulin signaling was modified for 1 hr prior to, or concurrently
with, the insulin challenge. However, to our knowledge, all
previous rodent studies have investigated the effects of sys-
temic hyperinsulinemia for 90–120 min on the background of
changes in brain insulin signaling that were in place for 4 hr to
life (Guo et al., 2009; Hill et al., 2010; Inoue et al., 2006; Koch
et al., 2008; Ko¨nner et al., 2007; Lin et al., 2010; Obici et al.,
2002a, 2002b; Ono et al., 2008; Park et al., 2009; Pocai et al.,
2005). Long-term changes in the insulin-brain-liver signaling
axis might alter the liver’s ability to respond to acute changes
in circulating insulin at the level of Akt phosphorylation, as has
been suggested (Hill et al., 2009; Park et al., 2009). It also
appears that chronic hypothalamic insulin resistance may
contribute to the development of hepatic insulin resistance (Hill
et al., 2009, 2010; Koch et al., 2008; Ko¨nner et al., 2007; Lin
et al., 2010; Ono et al., 2008; Park et al., 2009). However, human
type 2 diabetes has been shown to be associated with normal
levels of hepatic G6Pase and PEPCK mRNA (Samuel et al.,
2009), and it is currently unclear whether CNS insulin-regulated
hepatic genes are aberrantly controlled in diabetic humans. It
should also be noted that insulin has been shown to regulate
food intake, energy homeostasis, and body fat mass (Guyenetand Schwartz, 2012), and, thereby, chronic changes in brain
insulin action may indirectly affect the response of the liver to
the direct effects of insulin.
Postprandial conditions. Most studies to date have evaluated
the impact of CNS insulin signaling on the liver under euglycemic
conditions. In normal conditions, however, increased insulin
secretion is associated with the response to nutrient ingestion.
Thus, brain insulin action may be more relevant to the liver’s
response during times of nutrient excess (i.e., hyperglycemia).
In line with this, brain insulin action in the dog alters the expres-
sion of genes important to glucose uptake (glucokinase) and
glycogen synthesis (GSK3b). In addition, it has been suggested
that nutrient status may be important to brain insulin action in
the rodent (Lin et al., 2010). Nevertheless, it should be noted
that the suppression of HGP and the augmentation of net hepatic
glucose uptake during the acute meal response occurs too
quickly (within minutes) to involve genetic regulation unless the
response to the first meal of the day sets the tone for the hepatic
response to subsequent meals.
Alternatively, nongenomic effects of CNS insulin action may
become manifest under feeding conditions when hyperglycemia
exists. The delivery of glucose into the portal vein is known to
amplify net hepatic glucose uptake, relative to glucose delivery
into a peripheral vein, and this effect is manifest within minutes
(Cherrington, 1999). The portal glucose signal controls the dispo-
sition of glucose between muscle and liver, reducing uptake by
the former and enhancing uptake by the latter, without altering
overall whole-body glucose tolerance. The enhancement of net
hepatic glucose uptake by portal glucose delivery in the dog
requires the presence of insulin (Pagliassotti et al., 1992), tends
to increase with increasing levels of plasma insulin (Myers
et al., 1991), and appears to be sensitive to hepatic denervation
(Adkins-Marshall et al., 1992). Taking the above together, a role
for CNS insulin sensing in regulating postprandial net hepatic
glucose uptake cannot be ruled out. There is precedent for
CNS insulin action bringing about peripheral effects rapidly,
albeit not on the liver. For example, the sympathetic counter-
regulatory response to hypoglycemia, which occurs within
minutes and is responsible for the rapid life-saving rebound in
blood glucose, was amplified by elevated insulin in human
studies (Davis et al., 1993), an effect shown in rodents and
dogs to be due to the impact of increased CNS insulin action
(Davis et al., 1993, 1995; Diggs-Andrews et al., 2010; Fisher
et al., 2005).
Glucagon. It must be noted that the impact of glucagon
suppression is typically overlooked in studies evaluating CNS
insulin’s ability to suppress HGP. Rodent clamp studies evalu-
ating CNS insulin action typically do not measure or consider
the impact of the fall in plasma glucagon that is known to occur
in response to the effect of hyperinsulinemia on the a-cell
(Banarer et al., 2002; Kawamori et al., 2009). At the same time,
our pancreatic clamp studies in dogs have determined the
effects of CNS insulin action independent of the consequences
of changes in glucagon secretion because it was clamped at
a basal value. Recently, it was shown that local blockade of
basal insulin action in the hypothalamus can increase glucagon
secretion withinminutes in rats (Paranjape et al., 2010). Likewise,
hyperinsulinemia in dogs brought about by peripheral insulin
infusion decreased both glucagon secretion and C-peptideCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 661
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Perspectivelevels, indicative of decreased endogenous insulin secretion
and, therefore, decreased intra-islet insulin concentrations
(Cherrington, 2001). Thus, a-cell glucagon secretion was in-
hibited at a time when local insulin levels at the a-cell may
have been reduced, raising the possibility that this effect was
due to CNS insulin action. Evaluating the control of glucagon
by insulin in the brain becomes especially problematic during
meal-induced hyperinsulinemia, given the complexity of regula-
tion of the a-cell by nutrients, hormones, and neural input, as well
as autocrine and paracrine factors (Gromada et al., 2007). It
remains to be determined whether CNS insulin-mediated control
of glucagon secretion is of any significance to insulin’s effects
on HGP.
In summary, it is our view that, as with the rodent, the brain of
large animals can sense physiologic changes in plasma insulin
and relay that information to the liver and, perhaps, to other
tissues. Data available to date suggest that acute changes in
CNS insulin action bring about effects on hepatic gene transcrip-
tion. If this is indeed the mechanism by which brain insulin action
works, it would preclude its involvement in the rapid (<90 min)
response of the liver to insulin. Indeed, both rodent and canine
data indicate that the effect of brain insulin action on glucose
flux requires several hours or more to be manifest. This, in turn,
indicates that it is the noncentral effects of insulin on liver and
fat that drive the quick response of the liver to the hormone.
Further, rodent, dog, and human studies that have shown an
effect of CNS action on liver glucose flux (at 2 hr or greater)
have done so in the presence of relative hepatic insulin defi-
ciency. In the presence of normally elevated arterial and hepatic
insulin levels, where insulin levels at the liver are 3-fold greater
than at the brain, the central effects of insulin appear to be over-
ridden by the hormone’s direct effects on liver and fat. It is
possible that the impact of CNS insulin action varies among
species, given the differences in the basal metabolic rate and
hepatic innervation. Indeed, in the rodent the impact of brain
insulin action was gluconeogenic, whereas in the canine the
effect was on glycogen metabolism. In addition, it should be
remembered that chronic (hours to days) up- or downregulation
of brain insulin action may very well affect the acute response of
the liver to insulin by altering the baseline state of various glucor-
egulatory molecules. Finally, the role of CNS insulin action in
response to nutrient intake still needs clarification. Thus, there
is no doubt that the brain sensitively monitors the plasma insulin
level and signals the liver. This mechanism may be involved in
setting the basal tone for hepatic glucose metabolism, but there
is no evidence to support a role for an acute change in brain
insulin action in the rapid response of the liver to a rise in insulin
secretion. The key need at present is to find out under which
physiologic and pathologic conditions this regulatory mecha-
nism is important.
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